The partnership aims to provide access to clinical design expertise and the most appropriate analytical platform for early clinical investigations. Xceleron and JCL Bioassay have developed a combined 100 analytical methods for preclinical and Phase I investigations and both companies have recently built, equipped and staffed labs specific to ultra-low level analyses under GLP and GCP conditions.
“This partnership emphasizes the critical role of contemporary analytical platforms in driving down the cost of drug development. Whether in preclinical or enriched Phase I, we can confidently provide critical PK and PD information before Phase II,” said Dr. Michael Butler, chief executive officer of Xceleron.
“With 27 years’ experience in providing services for bioassay work coupled with-state-of-the-art analytical instruments, our researchers are well positioned to conduct ultrasensitive bioanalyses. The partnership with Xceleron further expands the geographic and technological scope of the services we can provide to our customers and promotes the use of these cutting-edge analytical platforms to detect low level analytes in early drug development,” said Jenny Lin, vice president of operations and chief scientific officer of JCL Bioassay USA, Inc.